Subscribe to GlobalData Explorer to access actionable intelligence spanning 22 industries, 200+ economies and 700k+ companies on a single platform

Number of ongoing Clinical Trials (for drugs) involving Pancreatitis by Phase

  • There are currently 69 ongoing clinical trials involving Pancreatitis

  • Of the 69 trials,20 trials are in Phase II

  • Furthermore, 20 trials are in Phase IV

Number of ongoing Clinical Trials (for drugs) involving Pancreatitis by Phase

Published: October 2021
Source: GlobalData

The global pharmaceutical industry is steadily developing new drugs for Pancreatitis, a gastrointestinal condition. The largest number of ongoing clinical trials for Pancreatitis is conducted in Asia-Pacific. North America and Europe are among some of the other prominent regions engaged in Pancreatitis-related drug trials.

West China Hospital of Sichuan University: The leading ongoing Pancreatitis related clinical trial sponsor

West China Hospital of Sichuan University is the top sponsor for Pancreatitis-related ongoing clinical trials.

West China Hospital of Sichuan University, Nanchang University Affiliated Hospital One, All India Institute of Medical Sciences and Postgraduate Institute of Medical Education and Research are among other notable clinical trial sponsors involved in Pancreatitis. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Pancreatitis

Cefoperazone Sodium and Sulbactam sodium (Sulperazone, Magnex, Magnex Forte), Ulinastatin (Miraclid), and Aztreonam (Azactam) are among the key marketed drugs involving Pancreatitis. 

Cefoperazone Sodium and Sulbactam sodium (Sulperazone, Magnex, Magnex Forte) is a fixed combination of cephalosporin antibiotic and beta-lactamase inhibitor. It functions via Beta Lactamase (EC 3.5.2.6) Inhibitor; Penicillin Binding Protein (PBP) Inhibitor mechanism of action. It is formulated as injectable powder for solution for intravenous route of administration. Cefoperazone Sodium and Sulbactam sodium is marketed for the treatment of Pancreatitis and several other indications including Urinary Tract Infections, Bacterial Conjunctivitis, Cholangitis, Cholecystitis, Acute Bronchitis, Bacterial Pneumonia, Pharyngitis, Gonorrhea, Bacterial (Pyogenic) Meningitis, Laryngitis, and Abdominal Abscess. Cefoperazone Sodium and Sulbactam sodium was was first approved in 1986 and is marketed in India, China, Indonesia, and Japan by Pfizer Inc

Ulinastatin (Miraclid) is a glycoprotein derived from human urine. It functions via Chymotrypsin (EC 3.4.21.1) Inhibitor; Elastase (EC 3.4.21.) Inhibitor; Trypsin (EC 3.4.21.4) Inhibitor mechanism of action. It is formulated as injection for intravenous route of administration. Miraclid is used for the treatment of acute pancreatitis, chronic recurrent pancreatitis and assistant medicine for rescue of acute circulatory failure. Miraclid was first approved in 1985 and is marketed in Japan by Mochida Pharmaceutical Co Ltd.



Explore, track and compare industries, economies and companies in a single platform through GlobalData Explorer.​

Single License $700 per month (billed Annually)
Multiple Licenses Connect with a GlobalData representative to discover our offers for multiple licenses​
  • 700K+Companies
  • 22Industries
  • 15K+Reports
  • 200+Countries & Regions
Still looking?

Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company Analytics

Contact the team or request a demo to find out how our data can drive your business forward